Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

INTRODUCTION: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244187/
https://www.ncbi.nlm.nih.gov/pubmed/31622733
http://dx.doi.org/10.1016/j.jtho.2019.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244187/
https://www.ncbi.nlm.nih.gov/pubmed/31622733
http://dx.doi.org/10.1016/j.jtho.2019.10.002

Ejemplares similares